Nature Reviews Endocrinology, Published online: 19 November 2026; doi:10.1038/s41574-026-01338-6 The introduction of glucagon-like peptide 1 receptor agonists (GLP1RAs) has transformed the care of patients with type 2 diabetes mellitus. Increasingly, evidence indicates that the benefits of GLP1RAs extend beyond lowering glucose levels; however, limited research has focused on diabetic sensorimotor polyneuropathy.
Gordon Sloan, Dinesh Selvarajah, Dan Ziegler, Solomon Tesfaye. Therapeutic potential of GLP1RAs in diabetic sensorimotor polyneuropathy. // Nature Reviews Endocrinology. – 2026. – DOI: 10.1038/s41574-026-01338-6. – URL: https://www.nature.com/articles/s41574-026-01338-6
Gordon Sloan, Dinesh Selvarajah, Dan Ziegler, & Solomon Tesfaye (2026). Therapeutic potential of GLP1RAs in diabetic sensorimotor polyneuropathy. Nature Reviews Endocrinology. https://doi.org/10.1038/s41574-026-01338-6
Gordon Sloan, et al. “Therapeutic potential of GLP1RAs in diabetic sensorimotor polyneuropathy.” Nature Reviews Endocrinology, 2026. doi:10.1038/s41574-026-01338-6.
@article{Sloan2026,
title = {Therapeutic potential of GLP1RAs in diabetic sensorimotor polyneuropathy},
author = {Sloan, Gordon and Selvarajah, Dinesh and Ziegler, Dan and Tesfaye, Solomon},
journal = {Nature Reviews Endocrinology},
year = {2026},
doi = {10.1038/s41574-026-01338-6},
url = {https://www.nature.com/articles/s41574-026-01338-6}
}